Search
for

    Learn

    5 / 65 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn Neem Oil

      natural substance from Neem tree with medicinal and pesticidal properties

      learn Caffeine

      the stimulant you know and love can be used topically to stimulate hair

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      by nkrata in Research  830 upvotes 1 year ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community Creatine is the opposite of minoxidil !

      in Research/Science  325 upvotes 4 months ago
      Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  40 upvotes 6 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.